Advertisement
Home »

Comparison and validation of different risk models for papillary renal cell carcinoma.

Jul 03, 2023

ABOUT THE CONTRIBUTORS

  • Haiyue Lin

    Department of Pathology, Xuzhou Medical University Affiliated Hospital of Lianyungang, Lianyungang, China.

    Qi Sun

    Department of Pathology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China; Department of Pathology, Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China.

    Zeyang Li

    Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, China.

    Jingmei Zheng

    Department of Pathology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China; Department of Pathology, Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China.

    Xue Zhang

    Department of Radiology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China.

    Ying Xiong

    Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: xiong.ying@zs-hospital.sh.cn.

    Hao Chen

    Department of Pathology, Xuzhou Medical University Affiliated Hospital of Lianyungang, Lianyungang, China.

    Yingyong Hou

    Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: hou.yingyong@zs-hospital.sh.cn.

    Wei Xi

    Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: xi.wei@zs-hospital.sh.cn.

    Jinglai Lin

    Department of Urology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China; Department of Urology, Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China. Electronic address: linjinglainbk@gmail.com.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement